Company intelligence / Profile preview

SentoClone International AB

Ownership: Private
Development stage: Phase 2

Overview

Over 200 patients with various cancers have been treated using the SentoClone® technology with no significant side effects reported. A Phase 2 clinical trial (NCT00991250) was conducted to investigate SentoClone® compared to reference treatment in advanced malignant melanoma[2][3].

Therapeutic areas: Oncology
Modalities: Cell therapyAutologous active cellular immunotherapy
Industry: Biotech

Drug pipeline

3 assets

X842

Phase 2

Indications: Gastroesophageal reflux disease

2 more assets in the full pipeline.

Beyond the preview

Go deeper on SentoClone International AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SentoClone International AB.